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There have been over 6,000 human heart transplants since the first transplant approximately 50 years ago.
In Japan, 50-60 transplants have been performed annually since enforcement of the revised Organ Transplant
Law; however, 600-700 people await transplantation, and even Status 1 patients wait over 1,000 days.
Post-transplant management is divided into two categories. One, related to transplantation itself, includes
open heart surgery, denervation/re-innervation, donor heart ischemia, and issues resulting from recipient heart
failure. The other consists of manageable factors such as rejection control, risk of infection or tumor under im-
munosuppression, adverse effects of immunosuppressants, and frequent cardiac catheterization procedures.
After transplantation, patients receive combined treatment with a calcineurin inhibitor (e.g., tacrolimus or
cyclosporine), mycophenolate mofetil, and a steroid. Antibody-mediated rejection and its relationship to cardiac
allograft vasculopathy have received significant attention. Immunosuppressants contribute to infection with
pathogens such as cytomegalovirus, Epstein-Barr virus, and hepatitis virus within 30 days after transplantation.
Cardiac allograft vasculopathy is characterized by diffuse coronary stenosis of mainly small- and medium-
sized arteries. It is diagnosed by intravascular ultrasound observation of intimal hyperplasia, a lesion caused by
immunologic and non-immunologic mechanisms and treated with mTOR (mammalian target of rapamycin) inhibi-
tors.
Compliance with post-transplantation maintenance therapies and behaviors enables good long-term health.
Heart transplantation is part of an ideal health care system, complemented by evidence- and narrative-based
medicine.
Key Words: heart transplantation, ventricular assist device, cardiac allograft vasculopathy, narrative-based medi-
cine, the transplant life
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Figure　1　Annual number of heart transplants worldwide according to the Registry of the 






























































あるか，つまり，NYHA（New York Heart Associa-
tion）心機能分類や米国心臓病学会/米国心臓協会
（ACC/AHA）の Stage分類，補助人工心臓（ven-
tricular assist device：VAD）か ら み た INTER-
MACS（Interagency Registry for Mechanically As-
sisted Circulatory Support）Profile分類〔日本におけ
る補助人工心臓に関連した市販後のデータ収集

















Figure　2　Determination of treatment strategies before heart transplantation based on re-
lationships between New York Heart Association (NYHA) classification, ACC/AHA stage 
classification, INTERMACS (J-MACS) profiles, and heart transplant waiting status.
NYHA, New York Heart Association; ACC/AHA, American Heart Association/American 
College of Cardiology; INTERMACS, Interagency Registry for Mechanically Assisted Cir-
culatory Support; J-MACS, Japanese registry for Mechanically Assisted Circulatory Sup-
port; VAD, ventricular assist device; IABP, intra-aortic balloon pumping; PCPS, percutane-
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至 る よ う な clinical cardiogenic shock（crash＆








注に依存した状態，すなわち stable but inotropic de-
pendentである profile 3や，入退院を繰り返す，いわ









Figure　3　Current number of people awaiting heart transplantation in the Japan Organ 







































































Figure　4　Relative incidences of leading causes of death in adult heart transplant patients 
from January 1994 to June 2017 according to the Registry of the International Society for 
Heart and Lung Transplantation-2018.
PTLD, posttransplant lymphoproliferative disorders; CAV, cardiac allograft vasculopathy. 
















































































Figure　5　Coronary angiogram and intravascular ultrasound (IVUS) images obtained 
2 years after heart transplantation in a 46-year-old recipient. The coronary angiogram 
showed slight irregularity of the vessel wall, but diffuse intimal hyperplasia was observed 






Figure　6　Role of the physician in heart transplantation.
EBM, evidence-based medicine; NBM, narrative-based medicine; mTOR, mammalian target 
of rapamycin; mTOR, mammalian target of rapamycin.
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